TG Therapeutics

is a biopharmaceutical company focused on the development of
novel treatments for B-cell malignancies and autoimmune diseases.

Click for full image >>

For Investors

NASDAQ: TGTX

Stock Quote at: Aug 18, 4:00PM EDT

Last: $10.85

Change: ($0.15) (1.36%)

Quotes provided by Google - Min 15 minute delay

News & Events

8.1.17

TG Therapeutics Announces Special Protocol Assessment (SPA) Agreement with the FDA for a Phase 3 Program of TG-1101 (ublituximab) for Patients with Multiple Sclerosis (MS)

8.7.17

TG Therapeutics to Host Conference Call on Second Quarter 2017 Financial Results and Business Update

Quick Links